It was a busy week in the biotech sector, with many regulatory and pipeline updates. Neumora Therapeutics NMRA plummeted on the announcement of a study failure, while Hoth Therapeutics HOTH gained on ...
Neumora Therapeutics (NMRA) announced results from the Phase 3 KOASTAL-1 Study of navacaprant for the treatment of major depressive disorder. The KOASTAL-1 Study is the first of three replicate ...
Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.
Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...
The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...
Massachusetts, USA-based based brain disease biotech Neumora Therapeutics shares tumbled 81.4% to 1.97 after it revealed that ...
Medpage Today on MSN1d
6% of Seniors Depressed; ADHD and Hormones; Novel Antipsychotic Eases SchizophreniaA study of older adults showed that 6% had depression, with higher prevalences in certain groups, including women, those who ...
The KOASTAL-1 study enrolled 383 adult patients with MDD. Navacaprant was shown to be safe and generally well-tolerated with ...
In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant ...
Neumora's KOASTAL-1 study results show navacaprant missed key goals in major depressive disorder. Additional studies and ...
Neumora Therapeutics ( NMRA) shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback